TNFSF4 and neoplasm: The combination of OX40L-FP and MVA-Twist-TRICOM significantly expanded the total number of CD4+Foxp3- T-cells at the metastatic tumor site (lung) by at least 2.1-fold compared to the individual treatments 28 days after tumor transplant (Figure 4A).